- Home
- OCUP
OCUP
Ocuphire Pharma Inc.
as 07-08-2024 4:00pm EST
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | FARMINGTON HILLS |
| Market Cap: | 39.5M | IPO Year: | N/A |
| Target Price: | $18.75 | AVG Volume (30 days): | 115.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.50 - $4.50 | Next Earning Date: | 08-09-2024 |
| Revenue: | $19,011,000 | Revenue Growth: | -54.30% |
| Revenue Growth (this year): | -12.43% | Revenue Growth (next year): | 297.75% |
Stock Insider Trading Activity of Ocuphire Pharma Inc. (OCUP)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jayagopal Ashwath | OCUP | Chief Scientific & Dev. Ofc. | May 22 '24 | Buy | $1.77 | 3,500 | $6,177.50 | 78,500 | SEC Form 4 |
| Magrath George | OCUP | Chief Executive Officer | May 17 '24 | Buy | $1.75 | 5,000 | $8,772.50 | 430,000 | SEC Form 4 |
| Jhaveri Nirav S. | OCUP | Chief Financial Officer | Mar 21 '24 | Buy | $2.10 | 10,000 | $21,000.00 | 150,000 | SEC Form 4 |
| SCHACHLE JOSEPH K | OCUP | Chief Operating Officer | Mar 21 '24 | Buy | $2.05 | 2,000 | $4,100.00 | 2,000 | SEC Form 4 |
| Magrath George | OCUP | Chief Executive Officer | Mar 18 '24 | Buy | $1.96 | 25,000 | $49,050.00 | 425,000 | SEC Form 4 |
Latest Ocuphire Pharma Inc. News
OCUP Breaking Stock News: Dive into OCUP Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
Simply Wall St.
2 months ago
Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations
GlobeNewswire
2 months ago
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire
2 months ago
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
GlobeNewswire
2 months ago
Ocuphire Pharma to Present at the Aegis Virtual Conference
GlobeNewswire
3 months ago
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
GlobeNewswire
3 months ago
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
GlobeNewswire
3 months ago
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Share on Social Networks:
Disclaimer
The information presented on this page, "OCUP Ocuphire Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.